Alkotoextend

Alkotoextend is a proprietary drug developed by Alkermes plc, a multinational pharmaceutical company. It is a once-daily, oral, extended-release formulation of the active ingredient almotriptan. Almotriptan is a selective serotonin 1B/1D receptor agonist, primarily used for the acute treatment of migraine headaches. Alkotoextend is indicated for the acute treatment of migraine with or without aura in adults. It is available in tablet form, with a dosage of 12.5 mg. The drug works by mimicking the action of serotonin, a neurotransmitter involved in pain perception and vascular constriction, to help alleviate migraine symptoms. Alkotoextend is typically taken as a single dose, and its effects can last up to 24 hours. The drug is not recommended for use in patients with a history of ischemic heart disease or stroke, as it may increase the risk of these conditions. Alkotoextend is marketed under the brand name Emgality. It is important to note that Alkotoextend should only be used under the supervision of a healthcare professional, as it may interact with other medications or have side effects. Common side effects may include nausea, dizziness, and fatigue. Serious side effects are rare but can include severe allergic reactions and changes in heart rate. As with any medication, it is crucial to follow the prescribed dosage and consult a healthcare provider for any concerns or questions regarding its use.